A Phase II Single Arm Study of Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression

Trial Profile

A Phase II Single Arm Study of Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jul 2018

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Hodgkin's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Jul 2018 Status changed from not yet recruiting to recruiting.
    • 16 May 2018 Planned initiation date changed from 1 Apr 2018 to 1 Jun 2018.
    • 18 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top